• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

REGN-COV2 antibody cocktail may reduces viral load in Covid-19 patients

byThomas SuandDeepti Shroff Karhade
January 25, 2021
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this interim analysis, patients who received REGN-COV2 had significantly greater decreases in viral load from baseline compared to those who received placebo.

2. Those who received REGN-COV2 were also only only half as likely to require additional medically attended visits compared to those in the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Most people who are infected with SARS-CoV-2 are either asymptomatic or can be treated on an outpatient basis, but a smaller subset develops hypoxemia and requires supplemental oxygen or hospitalization. These patients typically have high viral titers, leading many to hypothesize that reducing viral load may lead to a lesser likelihood of severe Covid-19. REGN-COV2 is a cocktail composed of equal amounts of two noncompeting, neutralizing human IgG1 antibodies (casirivimab and imdevimab) that both target the receptor-binding domain of the SARS-CoV-2 spike protein. In nonhuman primates, this formula has been shown to dramatically reduce viral replication when administered prophylactically and accelerate viral clearance when administered therapeutically. In the phase 1-2 portion of this ongoing trial involving adults with mild Covid-19, it was discovered that those who received REGN-COV2 had a significantly greater decrease in viral load compared to those who received placebo. This effect was rapid, with most reduction occurring within 2 days, and it was most pronounced in patients who were antibody-negative at baseline, which suggests that this treatment may be most effective in those whose endogenous immune systems have yet to be activated. Patients who received REGN-COV2 also had fewer medically attended visits related to Covid-19 compared to those in the placebo group. Serious adverse events were infrequent in both groups, and pharmacokinetics were linear and dose-proportional with no evidence of the development of antidrug antibodies. Of note, the half-life of the antibodies was longer than expected, suggesting that REGN-COV2 treatment may confer some degree of long-term passive immune.

Click here to read the study in NEJM

Relevant Reading: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

RELATED REPORTS

SARS-CoV-2 vaccination side effects associated with increased neutralizing antibodies

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers

In-Depth [randomized controlled trial]: In the phase 1-2 portion of this ongoing trial, 269 adult patients were randomly assigned in a 1:1:1 ratio to receive high dose REGN-COV2 (8.0 g), low-dose REGN-COV2 (2.4 g), or placebo intravenously. At baseline, 123 patients (45%) were serum antibody-positive, 113 (41%) were serum antibody-negative, and 39 (14%) had unknown antibody status. The serum antibody-positive patients and serum antibody-negative patients had median viral loads of 3.49 log10 copies per milliliter and 7.18 log10 copies per milliliter, respectively. Patients were followed through day 7 for changes in viral load and through day 29 for the frequency of Covid-19–related medically attended visits. Patients who received REGN-COV2 had greater reductions in viral load compared to placebo, with the least-squares mean differences from placebo being−0.25 log10 copies per milliliter (95% CI, −0.60 to 0.10) for the low-dose group, −0.56 log10 copies per milliliter (95% CI, −0.91 to −0.21) for the high-dose group, and −0.41 log10 copies per milliliter (95% CI, −0.71 to −0.10) for the combined group. This effect was driven primarily by patients who were serum antibody-negative at baseline; for this subgroup, the least-squares mean difference from placebo were −0.52 log10 copies per milliliter (95% confidence interval [CI], −1.04 to 0.00), −0.60 log10copies per milliliter (95% CI, −1.12 to −0.08), and −0.56 log10 copies per milliliter (95% CI, −1.02 to −0.11), respectively. Similarly, 6 of 182 patients (3%) in the combined REGN-COV2 group and 6 of 93 patients (6%) in the placebo group had a medically attended visit (relative difference, −49 percentage points; absolute difference, −3 percentage points; 95% CI, −16 to 9). Again, this effect was magnified in the the serum antibody-negative subgroup; 5 of 80 patients (6%) in the combined REGN-COV2 group had a medically attended visit compared to 5 of 33 patients (15%) in the placebo group (relative difference, −59 percentage points, absolute difference, −9 percentage points; 95% CI, −29 to 11).

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibodies
Previous Post

Pembrolizumab linked to longer cancer-free period in advanced colon cancer

Next Post

2 Minute Medicine Rewind January 25, 2021

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Infectious Disease

SARS-CoV-2 vaccination side effects associated with increased neutralizing antibodies

June 27, 2024
Clinical practice guidelines linked to improved bronchiolitis outcomes
Infectious Disease

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

May 13, 2022
#VisualAbstract: Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
StudyGraphics

#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers

February 17, 2021
#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin
StudyGraphics

#VisualAbstract: Clinical validity of SARS-CoV-2 antibodies

August 9, 2020
Next Post
CD45 T cell and macrophage infiltration characteristic of COVID-19 related lung injury

2 Minute Medicine Rewind January 25, 2021

Adalimumab aids in control of noninfectious uveitis

Schoolchildren aged 6-8 years experiencing increased prevalence of myopia following house confinement from COVID-19

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Multimodal pain regimen of generic medications following trauma found to achieve adequate pain control

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • Large language models show potential to provide feedback on research papers on a large-scale
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.